Clinical trial · Interventional
Horse Chestnut Seed Extract for Lymphedema
A Single-blind, Randomized Trial of Horse Chestnut Seed Extract for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors
NCT00213928CI-TRIAL-00018106completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To help Treat Lymphedema of the Arm in Breast Cancer Survivors with Horse chestnut Seed Extract
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphedema of Arm | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Horse Chestnut Seed Extract | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control
- type
- ACTIVE_COMPARATOR
- label
- Horse Chestnut Seed Extract
- description
- Horse chestnut seed extract (escins, aesins)
- interventionNames
- Drug: Horse Chestnut Seed Extract
Primary outcomes (1)
- measure
- Reduction of arm lymphedema
Secondary outcomes (3)
- measure
- - comparison of bioelectric impedance to measure lymphedema changes
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Patient demonstrates unilateral (ipsilateral to breast cancer resection side) lymphedema of the upper extremity. An extravascular water ratio of ³1.1/1 between the affected vs normal arm using multiple-frequency bioelectric impedance will be used as a criterion for lymphedema. There is not upper limit to the extent of arm volume (lymphedema) * Patient is greater than 6 months from last surgical and/or radiation treatment to the affected axilla. Exclusion Criteria: * Patients may not be receiving or be scheduled to receive cytotoxic or radiation chemotherapy treatment while on this lymphedema study (Last chemotherapy \> 4 weeks prior). Women who are being treated adjuvantly with tamoxifen, raloxifene, or an aromatase inhibitor remain eligible * Patients with a history of recurrent (more than 1 episode) arm cellulitis, prior or existing venous clot, or considered to have "woody" fibrosis of the affected arm are not eligible. Antibiotics used to treat any prior episode of cellulitis must have be completed no more recently than 3 months prior to initial screening.
References
Publications (0)
Data not yet available
No reference posted for this study.